AstraZeneca has recently acknowledged that its Covid-19 vaccine can lead to blood clots in rare cases, as reported by Telegraph on May 2. This admission comes after facing a class action lawsuit claiming that the vaccine, developed in partnership with Oxford University, caused death and serious injuries to multiple users. The first lawsuit, filed by Jamie Scott, alleged that the vaccine resulted in blood clots and brain bleeding, rendering him unable to work. A total of 51 lawsuits seeking compensation of up to £100 million have been brought before the Supreme Court.
Victims of these rare side effects have expressed frustration at the delayed response from the pharmaceutical company. Despite this, AstraZeneca has extended condolences to affected families and reaffirmed its commitment to user safety. The company maintains that the benefits of vaccination outweigh the potential risks of side effects. Regulators worldwide have consistently endorsed the safety and efficacy of the AstraZeneca vaccine, based on data from clinical trials and real-world usage.
Although AstraZeneca continues to deny the allegations, the company submitted a legal document to the high court in February acknowledging that the vaccine could potentially cause venous thromboembolism with thrombocytopenia syndrome (TTS) in extremely rare cases. The company emphasizes the need to investigate the specific cause of blood clotting in each individual instance. This admission follows prolonged legal disputes and may impact the outcome of the court cases.
In light of these developments, it is crucial for healthcare providers and authorities to monitor and address any adverse reactions associated with Covid-19 vaccinations. The focus should remain on ensuring
